IGM Biosciences (NASDAQ ... While Truist likes the new CEO and IGMS' leading position among TCEs, it awaits more signals on mechanistic viability and physician interest.

In yet another early year blow for the Bay Area’s biotech workforce, IGM Biosciences is laying off almost three-fourths of its staff after a crucial clinical study delivered poor results.